You are here

  • Home
  • Archive
  • Volume 10, Issue 6
  • Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

 

Online download statistics by month:

Online download statistics by month: June 2022 to March 2024

AbstractFullPdf
Jun 2022571594222
Jul 2022372381142
Aug 202215761593296
Sep 2022605633141
Oct 202241641880
Nov 202233534184
Dec 202221021172
Jan 202320320573
Feb 202320120596
Mar 202314014673
Apr 202312112148
May 202314114350
Jun 2023939437
Jul 2023888950
Aug 202312012134
Sep 2023777935
Oct 20239910144
Nov 202311412137
Dec 2023143143140
Jan 2024100103311
Feb 202412312660
Mar 202410410595
Total595260732220